BioLink Therapeutics, Machalandapur, Kalna (2025)

26/11/2025

🚀 BioLink Therapeutics Launches AI-Powered Drug Discovery Services for Academic Researchers

BioLink Therapeutics is proud to announce the advancement of our AI-powered drug discovery platform, designed to accelerate and democratize early-stage therapeutic innovation.

To strengthen scientific partnerships and validate the performance of our platform, we are now offering AI-driven drug-designing services to academic researchers at a nominal cost.
Our goal is simple: empower researchers with rapid, computation-backed molecule screening and design tools that can transform hypotheses into actionable therapeutic candidates.

🔬 Why BioLink?
Our platform integrates structure-based design, deep-learning–driven prediction models, and molecular optimization workflows to identify high-quality small-molecule leads. While we continue developing our internal pipelines in antimicrobial resistance (AMR) and cancer metastasis, we are equally committed to supporting the broader research community.

💡 An Invitation to Scientists & Innovators
If you are exploring new targets, testing therapeutic hypotheses, or seeking computational support for your research, BioLink Therapeutics is here to collaborate.

Advance your research with our validated, evolving, and purpose-built AI-powered drug designing platform.

📩 To collaborate or learn more, message us directly through website www.biolinktherapeutics.com

24/11/2025

⭐ Why Angel Investors Should Watch Early-Phase Startups Like BioLink Therapeutics

Angel investors look for early signs of resilience, ex*****on capacity, and scientific clarity - and BioLink Therapeutics stands exactly at that intersection. Startups that bootstrap their earliest milestones develop a level of discipline, efficiency, and strategic precision that funded startups often lack. BioLink has already demonstrated this rare combination:

✅ Secured a strategic collaboration with a reputed biotech company in India to advance a cancer detection technology toward IDE application - a milestone that typically requires significant early capital.

✅ Forged an academic collaboration with a leading IIT professor to validate AI-driven small-molecule designs against AMR, strengthening its preclinical therapeutics pipeline.

✅ Achieved acceptance into the prestigious C-CAMP Incubation Program, one of India's top biotech ecosystems, beginning November 1, 2025 - validation of scientific merit and innovation potential.

✅ Built a core scientific workforce, including hiring its first PhD Translational Scientist, entirely through bootstrapping.

These achievements signal a team capable of delivering high-value progress with minimal resources, reducing early-stage risk for investors.

For angel investors seeking ventures with strong scientific foundations, a diversified innovation pipeline, global health relevance, and founders who show unwavering grit, ex*****on power, and long-term strategic vision, BioLink Therapeutics is a startup that deserves early attention.
When such teams finally receive capital, they don’t experiment - they accelerate.

You may reach out to us by messaging through
website www.biolinktherapeutics.com

23/11/2025

A Call for Strategic Partners in Synthetic Chemistry: BioLink Therapeutics Is Building India’s First AI-Powered Drug Discovery Platform Against AMR

Antimicrobial resistance (AMR) is accelerating faster than the drugs we have to fight it. Globally, over 5 million deaths each year are linked to drug-resistant infections. India faces an even steeper challenge - treatment failures are rising, multidrug-resistant strains are spreading, and current antibiotics are rapidly losing effectiveness.

The unmet need is enormous.
The world urgently requires original drug discovery, especially from countries like India, where innovation must rise beyond the boundaries of generic drug production.

BioLink Therapeutics: Building India’s first AI-Powered Engine for New Molecules

At BioLink Therapeutics, we are developing an advanced AI-driven platform capable of designing novel, drug-like small molecules specifically against AMR mechanisms.

Our platform integrates:

* Predictive molecular modeling
* Structure–activity simulations
* Virtual screening of phytochemical derivatives and synthetic scaffolds
* ADMET and drug-likeness prediction
* Target-molecule interaction mapping

This ecosystem speeds up early discovery and produces high-confidence candidate molecules ready for synthesis and preclinical evaluation.

Strategic Scientific Partnerships With India’s Leading Institutes

To translate AI-designed molecules into validated therapeutic candidates, we have established collaborations with scientists from India’s premier institutions.

Together, we are building:

development pipelines
assays
vitro and early in vivo validation frameworks
-to-lab feedback loops for rapid optimization

But to accelerate the journey further, we need the right chemistry partners.

We Are Seeking Strategic Synthetic Chemistry Partners.

This message is specifically for companies with strong capabilities in:

✔ Small-molecule synthesis
✔ Scaffold modification
✔ Medicinal chemistry optimization
✔ Analytical characterization

We are actively looking for strategic collaborators who are passionate about co-developing first-in-class drug candidates against AMR.

India Must Lead in Original Drug Creation

India has built global reputation as the “pharmacy of the world,”
but the next era requires innovation, not replication.
Our mission is to position India as a creator of new molecular entities that address one of humanity’s greatest threats.

We invite chemistry-focused companies, CROs, pharma R&D teams, and research labs to collaborate with us and join this mission.

Let’s Co-Develop India’s Next Breakthrough Drugs

If you share this vision and can support synthetic chemistry capabilities, we would love to work with you.

👉 Please reach out through the message button on our website. www.biolinktherapeutics.com

Let’s unite our strengths, build novel molecules, and create life-saving therapies together.

17/11/2025

BioLink Therapeutics is attending a hands on workshop at C-CAMP, Bangalore from November 25 to November 28, 2025. This is not just another training program for us. It is a step forward in our mission to build affordable and impactful non invasive cancer diagnostic technologies for India.

https://lnkd.in/gjSSZaRS

Our founding team consists of PhD scientists with strong research depth and real world business development experience. With no seed fund we have already taken bold actions. We got incubated at C-CAMP. We signed an MOU with a reputed biotech company in India to co-develop and commercialize our cancer screening technology. We are moving with clarity focus and ex*****on discipline.

The workshop will train participants in device design microfabrication methods and assembly of lateral flow diagnostic kits through a complete learn by doing approach. For us it is an important opportunity. We aim to integrate these practical skills directly into our development pipeline. Our newly hired scientist, Dr. Priyobrata Sinha, will attend this workshop to enrich his skills.

By attending this program our goal is to sharpen our strategies to learn every technical detail needed and accelerate the creation of a functional prototype that can be validated with human samples for cancer detection.

Please connect us for business through message button within the website. We are open for angel investors.
www.biolinktherapeutics.com

16/11/2025

🌱 The Story of BioLink Therapeutics — Where We Stand and Where We’re Heading

Every startup has a moment when belief matters more than capital. For us at BioLink Therapeutics, that moment has defined our entire journey. We started with nothing but scientific clarity, conviction, and the courage to bootstrap our way forward.

Over the past months, we have quietly built momentum:

*We designed small molecules against AMR and cancer metastasis using our AI-powered drug discovery engine.
* We hired our first PhD translational scientist, strengthening our core research capability.
* We established a collaborative mission with a reputed biotech company in India to co-develop and validate our non-invasive cancer detection technology.
* We earned acceptance into C-CAMP Bangalore, gaining a scientific home for building our next-phase prototypes.

These milestones were not driven by funding - they were driven by discipline, strategic ex*****on, and the belief that meaningful science must start somewhere.

And now, as we enter the New Year, we are preparing for our next big leap.

BioLink Therapeutics is getting ready to reach out to angel investors, not for survival, but for expansion to raise seed capital that will allow us to initiate at least two IND-enabled studies. These studies will advance our AMR and oncology pipelines into real translational pathways.

We stand at the intersection of bootstrapping resilience and scientific ambition.
Our story is still being written but each milestone brings us closer to a future where affordable cancer diagnostics and novel therapeutics emerge from India to impact global health.

BioLink is advancing, the momentum is real, and the next chapter begins now.

Please reach out to us by messaging through website www.biolinktherapeutics.com

16/11/2025

BioLink Therapeutics Welcomes Its First PhD Translational Scientist: A Milestone in Our Bootstrapped Journey

BioLink Therapeutics is proud to announce a major milestone in its bootstrapped journey — the hiring of Dr. Priyobrata Sinha as our first PhD Translational Scientist. This marks a significant step forward as we move into prototype development and human sample validation for our affordable cancer screening technology.

Despite operating without external funding, BioLink has continued to advance its mission through determination, scientific rigor, and strategic partnerships. Our collaboration with Imgenex India accelerates the transition of our cancer screening platform from bench innovation to clinical readiness and Dr. Sinha will play a central role in this progress.

Dr. Sinha brings 10+ years of experience in molecular biology, biochemistry, assay development, PCR/qPCR, ELISA, Western blot, microscopy, cell culture, and animal handling. His background in translational research, scientific writing, problem-solving, mentoring, and critical thinking makes him an ideal fit for BioLink’s vision.

For a bootstrapped startup, hiring a full-time PhD scientist is more than a team expansion - it is a statement of BioLink’s long-term commitment to building affordable, accessible cancer diagnostics for India and bringing unmet solutions against antibacterial resistance and cancer metastasis.

With this milestone, BioLink Therapeutics continues to prove that innovation does not wait for funding - it moves forward with purpose, passion, and people who believe in the mission.

This is just the beginning.

01/11/2025

🚀 Mission in Motion | BioLink Therapeutics

From a vision shaped by translational research and entrepreneurial grit, BioLink Therapeutics continues to advance its mission — turning science into solutions for global health challenges.

Built entirely through bootstrapping, without any external seed funding, our journey reflects innovation powered by determination and purpose.

🌿 Our Recent Milestones
🔹 Partnered with a reputed biotech company in India (official media release coming soon) to advance our cancer detection technology toward IDE application — a significant step toward bringing biomarker-driven diagnostics to clinical reality.

🔹 Established an academic collaboration with an IIT professor (announcement forthcoming) to validate our AI-based drug discovery models and develop preclinical therapeutic interventions in antimicrobial resistance (AMR).
🔹 Accepted into the C-CAMP Incubation Program, Bangalore, beginning November 1,2025 marking the start of a new chapter.

🔹 Preparing to hire our first PhD Scientist, strengthening our translational research capabilities.

💡 Our Mission:
To accelerate AI-powered therapeutic and diagnostic innovations targeting AMR, neurodegeneration, and cancer, bridging the gap between academic discovery and industrial translation across India and the global biotech ecosystem.

Every step forward reaffirms our belief that impactful science can grow even without funding — when powered by vision, teamwork, and purpose.

Stay tuned — exciting updates ahead! 🌍✨

https://lnkd.in/eKHE9h9y
Email:therapeuticsbiolink@gmail.com

19/10/2025

🌟 Adjunct Instructor Position in Bioinformatics & Drug Discovery 🌟

Organization: BioLink Therapeutics LLP, INDIA
Program: Online Industrial Internship Program in Bioinformatics and Drug Discovery
Mode: Remote / Online

📢 About the Role
BioLink Therapeutics is seeking an Adjunct Instructor to lead and mentor students in our cutting-edge Online Industrial Internship Program, designed for Bachelor’s and Master’s students aspiring to enter the world of AI-driven drug discovery and computational biology.

This program bridges academic learning with real-world biotech applications, equipping students with skills in bioinformatics, molecular modeling, and AI-based drug design for therapeutic innovation.

👩‍🏫 Responsibilities
Deliver online training sessions in bioinformatics, molecular simulations, and computational drug discovery.

Mentor students on real-world projects and case studies.

Support development of research-driven modules that integrate academia with industrial applications.

🎓 Qualifications
PhD in Biophysics, Bioinformatics, or related field.

Strong background in computational biology, drug discovery, or related disciplines.

Prior teaching, mentoring, or industry experience preferred.

📬 How to Apply
Interested candidates are encouraged to email their CV and a brief statement of interest to:
📧 therapeuticsbiolink@gmail.com

15/10/2025

🚀 Exciting Announcement!
We are launching a Webinar on the Global Industrial Internship Program in Computational Drug Design – an advanced training initiative for bachelor’s and master’s students aspiring to lead innovation in pharmaceutical R&D.
🌍 What to Expect:
✅ Insights into our 30-hour structured training modules
✅ Overview of career benefits upon completion
✅ Introduction to our Program Director, Dr. Katherine Cole

https://biolinktherapeutics.com/media-release/dr-katharine-h-cole-joins-biolink-therapeutics-as-independent-director

✅ Real-world project assignment in drug design against a disease target

📢 Next Step:
If you are interested, please share your message of interest directly through our website. The date and time of the webinar will be announced soon.
This is your chance to gain industry-relevant expertise and prepare for impactful careers in computational drug design and pharmaceutical innovation.
Website: www.biolinktherapeutics.com

👉 Stay tuned for updates and secure your spot early!
&D

30/09/2025

BioLink Therapeutics has developed a groundbreaking colon cancer screening technology designed to deliver point-of-care results in just 15 minutes, significantly improving accessibility and early detection. The platform leverages a biomarker-driven approach, which holds strong promise for non-invasive diagnostic devices under potential Investigational Device Exemption (IDE) pathways. By combining rapid turnaround with zero invasiveness, the technology could play a pivotal role in expanding preventive screening to underserved populations. Looking ahead, BioLink is preparing to submit its regulatory approval package for clinical trials in 2026, underscoring its commitment to advancing cancer diagnostics through innovative, patient-friendly solutions in INDIA.
www.biolinktherapeutics.com

16/09/2025

Seed Funding & Founder Reality Check

Seed fund accelerates an idea to the next milestone. Without it, the journey becomes extremely challenging, and many founders lose motivation after repeated attempts to raise capital. Some thrive with early support—several unicorns stand as proof—while others face bankruptcy even after securing significant funding.

🌱 BioLink Therapeutics Story
Against the odds, BioLink Therapeutics has reached critical milestones without seed funding:

Its proprietary cancer detection technology advanced from bench research to clinical validation, aiming for an IDE application in mid-2026.

Its AI-powered drug discovery platform is ready for validation with designed small molecules against human diseases.

It has established academic collaboration with a renowned IIT professor to strengthen translational research.

🤝 The Road Ahead
BioLink is now in touch with angel investors and continues to engage with VC firms to secure the early-stage support essential for biotech startups.

✨ We believe this is just the beginning—turning cutting-edge science into real solutions for patients.

Message us through website
www.biolinktherapeutics.com

#

BioLink Therapeutics

26/11/2025

24/11/2025

23/11/2025

17/11/2025

16/11/2025

16/11/2025

01/11/2025

19/10/2025

15/10/2025

30/09/2025

16/09/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share